Status:
COMPLETED
Role of Positron Emission Tomography in the Evaluation of Response to Sorafenib in Advanced Hepatocellular Carcinoma
Lead Sponsor:
Hospital Miguel Servet
Collaborating Sponsors:
Fondo de Investigacion Sanitaria
Carlos III Health Institute
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Positron emission tomography (PET) with \[18F\]fluorodeoxyglucose (FDG-PET) evaluates cancer cell glycolysis(Warburg effect) as a surrogate for tumor response.The hypothesis of this study is that earl...
Detailed Description
Hepatocellular carcinoma (HCC) is a major health issue worldwide, particularly in Asia and Africa, and a disease that has increased in incidence in the Western world over the past 20 years primarily a...
Eligibility Criteria
Inclusion
- advanced hepatocellular carcinoma: diagnostic assessment by biopsy/cytology; in cirrhotic patients conventional radiologic criteria are also accepted
- more than 18 years of age.
- life expectancy greater than three months
- candidate to sorafenib therapy
- informed consent required
Exclusion
- hepatocellular carcinoma patients candidate to local/curative therapies(surgery/radiofrequency/TACE/other local therapy
- another active cancer than primary liver cancer
Key Trial Info
Start Date :
January 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2010
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT01157013
Start Date
January 1 2009
End Date
June 1 2010
Last Update
July 5 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Miguel Servet University Hospital
Zaragoza, Aragon, Spain, 50009